Urgent.News

What's breaking now, across thousands of outlets.

Tech

STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more

Merck is entering a research collaboration with Isomorphic Labs, the AI drug designer built on a Nobel-winning technology

STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more

Merck and Isomorphic Labs, a cutting-edge AI drug designer, have announced a research collaboration to discover potential small molecule candidates for a significant oncology target, according to STAT. This partnership, the latest in a series between a pharmaceutical giant and Isomorphic, aims to leverage Isomorphic's advanced drug design engine alongside Merck's existing wet lab data, focusing on preclinical and clinical development, manufacturing, and commercialization of any resulting products.

The U.S. Food and Drug Administration recently approved Sanofi's drug Infilbray, marking the first treatment for a rare genetic condition known as type 3 Gaucher disease. This disorder, primarily affecting the brain and nervous system, causes the accumulation of fatty substances within the body and brain. The FDA's approval was contingent on a late-stage study involving 43 patients aged 12 and above, who had already experienced stabilized symptoms outside the brain and nervous system through enzyme replacement therapy.

Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Also reported by 1 other outlet

Every outlet that reported this, and when →

Read the original at statnews.com →

More in Tech

More from Thursday 19 November →